GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Total Assets

Orphazyme AS (CHIX:ORPHAC) Total Assets : kr93.59 Mil (As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Total Assets?

Orphazyme AS's Total Assets for the quarter that ended in Jun. 2022 was kr93.59 Mil.

Total Assets is connected with ROA %. Orphazyme AS's annualized ROA % for the quarter that ended in Jun. 2022 was 188.84%. Total Assets is also linked to Revenue through Asset Turnover. Orphazyme AS's Asset Turnover for the quarter that ended in Jun. 2022 was 0.00.


Orphazyme AS Total Assets Historical Data

The historical data trend for Orphazyme AS's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Total Assets Chart

Orphazyme AS Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Total Assets
Get a 7-Day Free Trial 662.82 441.35 180.75 822.49 173.23

Orphazyme AS Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 676.36 822.49 428.03 173.23 93.59

Orphazyme AS Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Orphazyme AS's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as

Total Assets=Total Equity (A: Dec. 2021 )+Total Liabilities (A: Dec. 2021 )
=9.339+163.89
=173.23

Orphazyme AS's Total Assets for the quarter that ended in Jun. 2022 is calculated as

Total Assets=Total Equity (Q: Jun. 2022 )+Total Liabilities (Q: Jun. 2022 )
=78.205+15.384
=93.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orphazyme AS  (CHIX:ORPHAc) Total Assets Explanation

Total Assets is connected with ROA %.

Orphazyme AS's annualized ROA % for the quarter that ended in Jun. 2022 is

ROA %=Net Income (Q: Jun. 2022 )/( (Total Assets (Q: Dec. 2021 )+Total Assets (Q: Jun. 2022 ))/ count )
=251.932/( (173.229+93.589)/ 2 )
=251.932/133.409
=188.84 %

Note: The Net Income data used here is four times the quarterly (Jun. 2022) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Orphazyme AS's Asset Turnover for the quarter that ended in Jun. 2022 is

Asset Turnover
=Revenue (Q: Jun. 2022 )/( (Total Assets (Q: Dec. 2021 )+Total Assets (Q: Jun. 2022 ))/ count )
=0/( (173.229+93.589)/ 2 )
=0/133.409
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Orphazyme AS Total Assets Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Orphazyme AS (CHIX:ORPHAC) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines